Effects of Modafinil on Brain Function in Patients With Schizophrenia
Schizophrenia, Schizoaffective Disorder
About this trial
This is an interventional other trial for Schizophrenia focused on measuring Catecholamines, Dopamine, fMRI, Working Memory, Clinical Trial, Stabilization, Inpatients, Placebo, Modafinil, Normal Volunteers, Schizophrenia, Schizoaffective Disorder, Healthy Volunteer, HV
Eligibility Criteria
INCLUSION CRITERIA: Prior participation under NIH protocol # 95-M-0150, or new normal volunteers. Patients with Schizophrenia or Schizoaffective disorder that meet criteria for NIH protocol # 95-M-0150 will be included. No active Axis I or Axis II diagnosis in normal volunteers. Age range: 18-50 years. EXCLUSION CRITERIA: Subjects with a history of cardiovascular disease, liver disease and other medical illnesses, current active substance abuse or history of substance abuse for more than 5 years, and untreated or uncontrolled hypertension will be excluded. Individuals with persistent tardive dyskinesia will be excluded from the study. An electrocardiogram, blood pressure, pulse rate and metabolic panel including LFTs will be checked on all subjects prior to participation in the study. Schizophrenic patients taking, a COMT inhibitor, buproprion, stimulants, other cognitive enhancers or any illicit drugs of abuse, or MAO inhibitors will be excluded. Normal control subjects taking any medications affecting brain function will be excluded. Pregnant or breastfeeding women. Women of childbearing potential will undergo a urine pregnancy test the day the study initiates and screened by history for the possibility of pregnancy. Patients with significant history of violence against self or others as established in protocol # 89-M-0160 (Inpatient Evaluation of Neuropsychiatric Patients)
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike